-
74 new medicines are added to the medical insurance catalogue, including 7 rare disease medicines
Time of Update: 2021-12-31
Specifically, the rare disease drugs that have entered the medical insurance list through negotiations this time are human coagulation factor IX, icatibant acetate injection, noxinazan sodium injection, fampiridine sustained-release tablets, and agalsidase alpha.
Up to now, although the specific price of new drugs entering the medical insurance catalog has not been announced .
-
Shandong New Era, Chia Tai Tianqing... Siege 600 million antithrombotic drugs!
Time of Update: 2021-12-31
There are 7 manufacturers of argatroban injection including Tianjin Pharmaceutical Research Institute Pharmaceutical, Shandong New Times Pharmaceutical, Nanjing Zhengda Tianqing Pharmaceutical, etc.
There are 7 manufacturers of argatroban injection including Tianjin Pharmaceutical Research Institute Pharmaceutical, Shandong New Times Pharmaceutical, Nanjing Zhengda Tianqing Pharmaceutical, etc.
-
This field of drug research and development is ushering in a new situation!
Time of Update: 2021-12-31
For example, Ai Diweixin Biopharmaceuticals announced in June this year that the vaccine candidate ADV110 in its research and development pipeline used to prevent diseases caused by respiratory syncytial virus (RSV) infection has successfully completed the first batch of subjects in the Phase II clinical study in Australia .
-
The concept of big health continues to be hot, and another pharmaceutical company chooses cross-border tea
Time of Update: 2021-12-31
In addition to tea, business areas such as daily chemicals, beauty and even lotteries have also become cross-border choices of pharmaceutical companies in recent years .
-
Osaikang launches 700 million anti-tumor injections!
Time of Update: 2021-12-31
0 Chinese Drug Evaluation Database In March of this year, Nanjing Hairun Pharmaceutical, a subsidiary of Beijing Aosaikang Pharmaceutical , was approved for production of dexrazoxane for injection in 3 types of imitations, which was deemed to have been reviewed .
-
Recently, the intensive issuance of pharmaceutical theme funds, the industry: the pharmaceutical sector ushered in opportunities for bargaining
Time of Update: 2021-12-31
Now entering the end of the year, the pharmaceutical theme fund has begun to be issued intensively, and the industry believes that the pharmaceutical sector has entered a bargain-hunting phase .
-
The innovation capabilities of local pharmaceutical companies continue to improve, and domestic new drugs are accelerating their advancement into medical insurance
Time of Update: 2021-12-31
Among them, it is worth noting that many of the drugs entering the medical insurance this time are innovative drugs of pharmaceutical companies, covering cardiovascular, tumor, rare diseases and other fields .
-
Digital healthcare is welcoming the trend, and it has become a battleground for domestic and foreign pharmaceutical companies
Time of Update: 2021-12-31
At the same time, in China, a large number of multinational pharmaceutical companies are also accelerating their deployment in the domestic digital medical field through cooperation with domestic Internet platforms and medical companies .
-
AstraZeneca over US$3.5 billion and Ionis to develop a new antisense oligonucleotide drug under development
Time of Update: 2021-12-31
On December 7, AstraZeneca and Ionis Pharmaceuticals (hereinafter referred to as "Ionis") announced that an antisense oligonucleotide (ASO) eplontersen (IONIS-TTR-LRX) of the latter under development has reached over 35.
Billion-dollar global development and commercialization agreement .
Eplontersen is the fifth drug developed by Ionis and AstraZeneca.
-
After entering the medical insurance catalog, a group of pharmaceutical companies said they would actively prepare production capacity
Time of Update: 2021-12-31
"Under the background that the price reduction of drugs in the medical insurance catalogue has become a general trend, how can we further ensure product quality while meeting demand?
-
In order to explore emerging R&D opportunities, the two pharmaceutical companies have reached a cooperation!
Time of Update: 2021-12-31
. At the same time, the two parties will explore and promote the access of innovative treatment plans under the "Hong Kong and Macau Medicines and Devices Access" and other relevant pilot policies for the access of innovative drugs and medical devices, so as to benefit patients as soon as possible and provide them with more treatment options .
-
Langyu Group and Rhythm reached an exclusive license agreement for rare genetic obesity drugs
Time of Update: 2021-12-31
According to the terms of the agreement, Langyu will first seek regulatory approval and commercialization in China for certain indications, including: POMC biallelic defects, PCSK1 biallelic defects, LEPR biallelic defects, and Bardet-Biedl comprehensive Obesity and binge eating are rare diseases caused by symptoms or Alström syndrome .
-
This week, there are many new changes in the executives of pharmaceutical companies
Time of Update: 2021-12-31
Zhu Jun, the current Chief Medical Officer and Senior Vice President, takes over as President and is responsible for the company's global product development and management of some functional departments .
-
The rise of domestic insulin after centralized procurement is imminent, and this field will also usher in an explosion
Time of Update: 2021-12-31
The market generally believes that the rise of domestic insulin after centralized procurement is imminent, and the market structure of long-term monopoly by imported manufacturers is expected to be reshaped.
-
Under multiple pressures, pharmaceutical companies still have strong demand for medical representatives
Time of Update: 2021-12-31
Pharmaceutical companies still need professional medical representatives to process information and promote new drugs .
. It is reported that the Cinda Bio&Blood team is currently recruiting medical representatives to be responsible for Dabova (rituximab) and third-generation Tki (oribatinib) to be listed at the end of the year .
-
On the evening of December 3, the announcements of these listed pharmaceutical companies were interesting
Time of Update: 2021-12-31
Iris announced that the company's self-developed Class 1 new drug, Vometinib Mesylate, was included in the National Medical Insurance List for the first time .
-
A box of 860!
Time of Update: 2021-12-31
It is reported that Beijing Tongrentang issued a price adjustment notice, raising the selling price of Angong Niuhuang Pills (3g*pills/box) from 780 yuan to 860 yuan, an increase of about 10%.
-
Interpretation of CDE's newly released document-"Technical Guidelines for Long-term Follow-up Clinical Research of Gene Therapy Products"
Time of Update: 2021-12-31
In order to guide and standardize the clinical trials of gene therapy products, on December 3, 2021, the official website of the Center for Drug Evaluation of the National Medical Products Administra
-
14 selected medicines in centralized procurement will be investigated!
Time of Update: 2021-12-31
Among them, the document mentioned that in the process of monitoring the national centralized procurement of drugs, the Yunnan Provincial Medical Insurance Bureau found that some selected companies failed to supply the selected drugs in time and in accordance with the needs of medical institutions.
-
Simcere's 2 new anti-tumor drugs SIM1811-03 and paxalisib were approved for clinical use
Time of Update: 2021-12-31
They are: the self-developed anti-TNFR2 antibody SIM1811-03, It is intended to be used for the treatment of advanced solid tumors and skin T-cell lymphoma; the PI3K/mTOR pathway inhibitor paxalisib, which was introduced over US$290 million, is intended to be used for newly diagnosed and relapsed glioblastoma (GBM) .
